Livzon Pharmaceutical Group Inc

Livzon Pharmaceutical Group Inc maintains a strong liquidity position, with a current ratio of 2.23, indicating the company can cover its short-term liabilities with its short-term assets. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity risk. The debt-to-equity ratio of 0.22 suggests a relatively conservative capital structure, with a low reliance on debt financing. In terms of profitability, Livzon's return on equity (ROE) of 14.57% and return on assets (ROA) of 8.44% are strong indicators of efficient capital use and asset management. These metrics are well above the typical thresholds for the pharmaceutical industry, suggesting that the company is generating solid returns for its shareholders. Livzon's revenue is primarily concentrated in its domestic market, with a significant portion of its operations based in China. The company's exposure to geographic and regulatory risks is therefore tied to the Chinese market, which may be subject to policy changes and economic fluctuations. The company does not disclose detailed segment breakdowns, but its core business appears to be focused on pharmaceutical products and related services. Looking ahead, Livzon is expected to maintain a stable growth trajectory, with analysts providing a mean price target of 34.41 CNY and a median of 34.90 CNY. The company's free cash flow of 1.38 billion CNY and operating cash flow of 3.15 billion CNY support its ability to fund operations and potentially invest in growth opportunities. However, the company's capital expenditures are negative, indicating a reduction in investment in physical assets. The risk assessment for Livzon highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in the event of a liquidity crunch. The dilution risk is low, with no significant dilution expected in the near term. The company's capital structure remains relatively stable, with a low debt-to-equity ratio. Recent events and filings indicate that Livzon has not disclosed any major strategic shifts or significant regulatory challenges in the latest financial reports. The company's financial performance remains consistent with its historical trends, and there are no immediate signs of distress or major operational disruptions.